Echinococcus vogeli is a tapeworm that can cause polycystic hydatid disease in humans. This disease is characterized by the growth of multiple cysts in various organs, including the liver, lungs, and spleen.

The key antigen of E. vogeli is Antigen B, which is like the Antigen B of Echinococcus granulosus and Echinococcus multilocularis. Antigen B is a complex molecule that is composed of multiple subunits and is located on the surface of the parasite.

Antigen B has been shown to be highly immunogenic in both animal models and humans, making it a potential target for the development of diagnostic tests and vaccines against E. vogeli infection. One study found that individuals infected with E. vogeli had significantly higher levels of antibodies against Antigen B than uninfected individuals, suggesting that it could be a useful diagnostic marker for the disease.

In addition to its potential as a diagnostic marker, Antigen B is also being investigated as a potential target for immunological interventions against E. vogeli infection. Studies have shown that vaccination with Antigen B can confer host-protective immunity in animal models, suggesting that it may be a promising target for vaccine development against polycystic hydatid disease.

Overall, ongoing research into the immunology and pathogenesis of E. vogeli infection will be crucial for the development of effective diagnostic tests and vaccines against the disease. By targeting key antigens such as Antigen B, it may be possible to develop new tools to combat this important zoonotic disease and improve the health of both animals and humans.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The cDNA (complementary DNA) and recombinant antigens of Echinococcus vogeli have several potential applications, including:
Diagnosis: The recombinant antigen of Echinococcus vogeli can be used to detect the presence of specific antibodies in the host, which indicates an active or past infection. Serological tests, such as ELISA and Western blotting, can be used to detect the antibodies. Additionally, PCR (polymerase chain reaction) can be used to detect the parasite’s DNA in tissue samples.